Xinfuda can discuss cartridge fit, plunger movement, dose volume, cap structure and assembly requirements during the project evaluation stage
typically dose-related and diminishing over time Serious risks : Pancreatitis (rare), gallbladder events, thyroid C-cell tumor boxed warning (from rodent studies) Dose escalation : Slow titration (0.25 mg escalating monthly) mitigates GI tolerability Strength : The safety database is massive, with well-defined risk-benefit profile across multiple patient populations Survodutide Side Effects# Less well-characterized with limited clinical exposure: GI effects : Expected GLP-1 class effects (nausea, vomiting, diarrhea) observed in Phase 2 Glucagon-specific concerns : Potential for hepatic glucose output increase (mitigated by GLP-1 component), theoretical impact on blood glucose in diabetic populations Heart rate : Glucagon receptor agonism may affect heart rate
Market Context: This move targets a rapidly growing 1,109 Cr anti-obesity market where Mounjaro has already captured nearly 500 Cr in seven months
Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation
Skin aging and oxidative stress
doi: 10.1093/nar/gkv679 297 WatanabeM.Dykes-HobergM.Cizewski CulottaV.PriceD
